Patented Strain · Documented Record · Published Research
We are EnergyMax Group Ireland, the Irish and EU distributor of Maxilin — a synbiotic built on one named, patented bacterial strain with a clinical record you can look up yourself.
At Maxilin Ireland (EnergyMax Group Ireland) we believe real gut-health innovation is built on rigorous scientific verification — not on white-labelled claims or generic bacterial blends.
Most off-the-shelf probiotics are sold on unverified strain blends and self-declared marketing copy. Maxilin is different in a way you can check. It rests on a single identified organism — Lactobacillus acidophilus strain 2585, culture 2585-1666 — carried through a documented development history, registered in 1993 by the Pharmacological Commission of the Kazakh Ministry of Health under Protocol No. 12, protected by Eurasian Patent No. 014227 B1, and described in a publication indexed on PubMed.
Our job in Ireland is not to reinvent that record. It is to make it legible: to publish the source documents in full, to say plainly what each one does and does not establish, and to let you verify the parts that are independently verifiable.
The right-hand column describes the general state of the mass-market probiotic shelf, where strain identity and testing are frequently undisclosed. It is a category comparison, not a claim about any named competitor product.
| Validation criteria | Maxilin (L. acidophilus strain 2585) | Typical commercial probiotic |
|---|---|---|
| Bacterial strain identity | ✔ L. acidophilus strain 2585, culture 2585-1666 — named and traceable | ✖ Genus and species only; specific strain often undisclosed |
| Patent verification | ✔ Eurasian Patent No. 014227 B1, granted 29 October 2010; Kazakhstan national patent No. 14850 | ✖ Unpatented, or a “proprietary blend” with no published filing |
| Regulatory & ministry review | ✔ Pharmacological Commission Protocol No. 12, 19 February 1993; clinical-use instructions approved 1993 and 1994 | ✖ Food-supplement notification only |
| Institutional clinical setting | ✔ Kazakh National Medical University research; acts recorded at the Central Clinical Hospital, Republican Polyclinic and Institute of Pediatrics, Almaty | ✖ Unpublished in-house testing |
| Indexed literature | ✔ Stomatologiia (Moskva) 2000;79(4):22–27 — PMID 10961107, strain-specific | ✖ Generic citations about probiotics in general, not the strain sold |
| Professional backing | ✔ 2013 statement from the Association of Nutritionists, Gastroenterologists and Endoscopists of Kazakhstan (ANGEK), chaired by Prof. E. A. Izatullaev | ✖ Paid or self-declared promotional endorsement |
| Independent batch testing | ✔ Almaty Technological University Test Report No. 798, September 2024 — 20 billion CFU lactic-acid microorganisms, zero coliforms | ✖ Label CFU figure with no third-party verification published |
Maxilin was not formulated to a marketing brief. It came out of a long development programme, and the dated record below is the part of that story backed by documents we publish.
1908–1980s · Origin and strain development
At a Tokyo microbiology symposium, Galina Maksimovna — a Candidate of Biological Sciences — answered a Japanese presentation on a dangerous new microbe with a promise to create a microbe that would defeat it. That challenge set the programme in motion.
Two natural sources — animal biological material and human neonatal meconium — were isolated, adapted and refined across decades into L. acidophilus 2585, selected for resilience and for antagonistic behaviour towards opportunistic organisms. The strain was not genetically modified.
Roughly ten years of adaptation work produced a strain that survives an antibiotic course — confirmed tolerant to streptomycin, neomycin, monomycin, chloramphenicol and gentamicin — so a prescription need not wipe out the beneficial flora with the harmful.
1993–1994 · Ministry approval and supervised clinical use
Registered as a natural medicine by the Pharmacological Commission of the Kazakh Ministry of Health under Protocol No. 12, with clinical-use instructions approved in 1993 and again in 1994.
Used for dysbacteriosis at the 1st Polyclinic Association in Almaty.
Gynaecology records at the Republican Military Polyclinic documented restoration of healthy flora within five to seven days; the Institute of Pediatrics in Almaty documented supervised paediatric use for intestinal dysbacteriosis. Research sat with the Kazakh National Medical University, with acts recorded at the Central Clinical Hospital.
2000–present · Publication, patent and verification
Pichkhadze G.M., Rusanov V.P., Novoselov V.E., Stomatologiia (Moskva) 2000;79(4):22–27. Strain 2585 was tested against four clinically significant organisms isolated from patients with open mandibular fractures under active wound infection — Candida albicans, Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli — with measurable antagonistic activity reported against all four, most pronounced against C. albicans.
Granted for the method of obtaining Maxilin and correcting microflora in humans and animals, following Kazakhstan national patent No. 14850 filed on 19 March 2004.
The Association of Nutritionists, Gastroenterologists and Endoscopists of Kazakhstan, chaired by Prof. E. A. Izatullaev, issued a statement on culture 2585-1666 and reaffirmed age-based dosing. It remains the most recent formal professional endorsement in the document set.
Almaty Technological University Test Report No. 798 confirmed 20 billion CFU of lactic-acid microorganisms per sachet and zero coliforms.
EnergyMax Global Private Limited received FSSAI Central License No. 12725999000778 in India, alongside continuing distribution across Ireland, the EU and the CIS region.
Maxilin is a lyophilised (freeze-dried) synbiotic: live probiotic bacteria — L. acidophilus strain 2585 — packaged together with the prebiotic inulin that feeds them.
Lyophilisation holds the culture in a dormant, stable state so potency is preserved without artificial chemical additives or synthetic preservatives. The dry form keeps at 20–25°C in low humidity, with a shelf life of up to two years.
After drying, the manufacturer BIODEP applies its multi-layer micro-coating (ProCap™) to the powder, insulating individual cells against ambient moisture and the acidity of gastric transit so the bacteria reach the intestine to do their work.
Each sachet carries 20 billion colony-forming units to support microbiome diversity, with inulin on hand to feed the culture once it arrives. The September 2024 Almaty Technological University report verified that count independently.
Enquiries are handled personally, in English, by Terry Protoules — not by an automated sales sequence. We supply Ireland, the EU and worldwide, including India, Kazakhstan and the wider CIS region.